SOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

SOPHiA GENETICS (NASDAQ:SOPH) posted its quarterly earnings data on Tuesday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04), Zacks reports. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• Q1 results — revenue of $21.7M (+22% YoY), a record 108,000 genomic analyses, and a 75.4% adjusted gross margin, which management says demonstrates the platform’s scalability.
• Network and retention — 537 institutional customers across 75 countries and ~2.5M profiles since inception; net dollar retention rose to 117% with multiple >$1M ACV expansion deals, supporting in-account upsell momentum.
• Biopharma traction — accelerating engagement with partners including AstraZeneca and J&J, plus efforts to build a global CDx and real-world evidence offering that management expects will be a material growth driver.
• Outlook and profitability path — the company reaffirmed 2026 revenue guidance of $92–$94M (20–22% growth) and adjusted EBITDA loss guidance of $29–$32M, and expects to approach adjusted-EBITDA breakeven by end-2026 and turn positive in H2 2027.
• Risks and headwinds — ongoing Guardant patent litigation (Q1 legal expense ~$1.4M, net ~$700k after interim recoveries), Swiss franc FX translation pressure raising dollar-reported costs, softness in Latin America, and elevated Q1 cash burn of $19.5M despite $65.4M cash on hand.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock traded down $0.16 during mid-day trading on Tuesday, hitting $5.14. The stock had a trading volume of 48,121 shares, compared to its average volume of 166,303. The firm has a market capitalization of $351.70 million, a P/E ratio of -10.07 and a beta of 1.01. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The firm’s 50 day moving average is $4.81 and its 200 day moving average is $4.78. SOPHiA GENETICS has a one year low of $2.59 and a one year high of $5.70.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Guggenheim upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research upped their target price on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

Insiders Place Their Bets

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 43,129 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total transaction of $213,919.84. Following the completion of the transaction, the chief executive officer owned 3,664,440 shares of the company’s stock, valued at $18,175,622.40. This represents a 1.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 193,859 shares of company stock valued at $943,777. Corporate insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at about $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $54,000. XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $55,000. Susquehanna International Group LLP bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at about $88,000. Finally, Polen Capital Management LLC bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $102,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.